A liquid chromatography–tandem mass spectrometry method for therapeutic drug monitoring of treosulfan
Laboratory Medicine · 03.04.2026 · 57 (3)
DOI: 10.1093/labmed/lmag017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laboratory Medicine, online erschienen am 28.04.2026. Verfasst von Jeayeon Ryu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Busulfan, Tandem Mass Spectrometry, Drug Monitoring, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Introduction
Treosulfan is an alkylating agent administered before hematopoietic stem cell transplantation. Because pharmacokinetic parameters exhibit interindividual variability, therapeutic drug monitoring may be necessary. In this study, a liquid chromatography–tandem mass spectrometry method for monitoring treosulfan was developed and validated.
Methods
Treosulfan was separated from 25 µL plasma after protein precipitation with acetonitrile. Treosulfan-D4 was used as the internal standard. Separation was performed using an ACQUITY UPLC Ι-Class PLUS System (Waters Corporation) coupled with a Xevo TQ-XS Mass Spectrometer (Waters Corporation). Limit of quantification, selectivity, linearity, imprecision, carryover, matrix effect, and stability were validated according to Clinical and Laboratory Standards Institute guidelines.
Results
The mass-to-charge transitions were treosulfan 296.2 > 87.1 and treosulfan-D4 300.2 > 91.1. The total run time was 4 minutes. The limit of quantification of treosulfan was 3.13 µg/mL. The calibration curve was linear in the 3.13 to 100-µg/mL range. The method was adequately selective and without carryover or matrix effect. Treosulfan was stable in plasma for 2 hours at room temperature and for up to 3 days and 1 week when stored at 10 °C and ‒20 °C, respectively.
Discussion
Our liquid chromatography–tandem mass spectrometry method for measuring treosulfan met Clinical and Laboratory Standards Institute validation requirements and exhibited robust performance, suggesting its utility for therapeutic drug monitoring in clinics treating patients with treosulfan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea.
- Institute of Digital Healthcare, University of Ulsan College of Medicine, Seoul, Korea.
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan, College of Medicine, Seoul, Korea.
ORCID-Profile: Jeayeon Ryu, Sollip Kim, Sang-Hee Lee, Sung Han Kang, Woochang Lee, Sail Chun, Ho Joon Im
Zitieren
APA
Ryu, J., Kim, S., Lee, S. H., Kang, S. H., Lee, W., Chun, S., & Im, H. J. (2026). A liquid chromatography–tandem mass spectrometry method for therapeutic drug monitoring of treosulfan. Laboratory Medicine, 57(3). https://doi.org/10.1093/labmed/lmag017
Vancouver
Ryu J, Kim S, Lee SH, Kang SH, Lee W, Chun S, et al. A liquid chromatography–tandem mass spectrometry method for therapeutic drug monitoring of treosulfan. Laboratory Medicine. 2026;57(3). doi:10.1093/labmed/lmag017
BibTeX
@article{Ryu2026,
author = {Ryu, Jeayeon and Kim, Sollip and Lee, Sang-Hee and Kang, Sung Han and Lee, Woochang and Chun, Sail and Im, Ho Joon},
title = {A liquid chromatography–tandem mass spectrometry method for therapeutic drug monitoring of treosulfan},
journal = {Laboratory Medicine},
year = {2026},
volume = {57},
number = {3},
doi = {10.1093/labmed/lmag017}
}
EUVIMED